You are here: Industry Insights > MC2

News List

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis b3cnewswire
December 25, 2019
MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology based topical therapies for chronic inflammatory conditionss, announced that its EU Phase 3 trial (n=490) on the company’s investigational drug ...
MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis b3cnewswire
November 26, 2019
MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions ...
MC2 Therapeutics reports positive Phase III results for experimental psoriasis cream firstwordpharma
August 22, 2018
MC2 Therapeutics on Tuesday announced that its investigational psoriasis cream MC2-01 (calcipotriene/betamethasone) demonstrated "significant superiority" in a Phase III trial in terms of both treatment......
MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris b3cnewswire
October 13, 2017
MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream (calcipotriene and betamethasone